Citadel Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-56,839
| Closed | -$30K | – | 5621 |
|
|
2019
Q4 | $30K | Buy |
56,839
+41,984
| +283% | +$22.2K | ﹤0.01% | 4465 |
|
|
2019
Q3 | $57K | Sell |
14,855
-16,259
| -52% | -$62.4K | ﹤0.01% | 4342 |
|
|
2019
Q2 | $207K | Buy |
31,114
+16,324
| +110% | +$109K | ﹤0.01% | 4105 |
|
|
2019
Q1 | $53K | Sell |
14,790
-363
| -2% | -$1.3K | ﹤0.01% | 4219 |
|
|
2018
Q4 | $60K | Buy |
15,153
+2,515
| +20% | +$9.96K | ﹤0.01% | 4086 |
|
|
2018
Q3 | $250K | Sell |
12,638
-2,158
| -15% | -$42.7K | ﹤0.01% | 3605 |
|
|
2018
Q2 | $469K | Buy |
14,796
+12,421
| +523% | +$394K | ﹤0.01% | 3174 |
|
|
2018
Q1 | $88K | Sell |
2,375
-1,373
| -37% | -$50.9K | ﹤0.01% | 3651 |
|
|
2017
Q4 | $296K | Buy |
+3,748
| New | +$296K | ﹤0.01% | 3152 |
|